Universal Beteiligungs und Servicegesellschaft mbH Takes $5.51 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 130,853 shares of the biopharmaceutical company's stock, valued at approximately $5,505,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.14% of Ultragenyx Pharmaceutical as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. KBC Group NV raised its holdings in Ultragenyx Pharmaceutical by 2,275.8% in the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock valued at $2,567,000 after buying an additional 58,442 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 19,580 shares of the biopharmaceutical company's stock valued at $824,000 after acquiring an additional 1,854 shares during the last quarter. abrdn plc raised its stake in shares of Ultragenyx Pharmaceutical by 25.2% in the 4th quarter. abrdn plc now owns 317,125 shares of the biopharmaceutical company's stock valued at $13,341,000 after acquiring an additional 63,821 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its position in shares of Ultragenyx Pharmaceutical by 33.8% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 46,514 shares of the biopharmaceutical company's stock worth $1,957,000 after purchasing an additional 11,745 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 2,547 shares of company stock valued at $101,015 over the last three months. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Trading Up 0.6%

Shares of RARE stock traded up $0.21 on Wednesday, reaching $36.61. 759,203 shares of the stock were exchanged, compared to its average volume of 840,220. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -5.77 and a beta of 0.34. The business's 50 day moving average price is $35.50 and its 200 day moving average price is $40.50. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the prior year, the company posted ($2.03) earnings per share. The company's revenue was up 28.0% compared to the same quarter last year. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on RARE. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Piper Sandler reduced their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Canaccord Genuity Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Finally, William Blair started coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $88.77.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.